Prof. Oliver Dorigo
keynote Talk: Tumor associated Macrophages in Ovarian Cancer
Director, Division Gynecologic Oncology and
Director, Stanford Gynecologic Oncology Clinical Care Program
Stanford University, Stanford, US
keynote Talk: Tumor associated Macrophages in Ovarian Cancer
Director, Division Gynecologic Oncology and
Director, Stanford Gynecologic Oncology Clinical Care Program
Stanford University, Stanford, US
Vaccines for breast cancer prevention
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Dendritic Cells: Cancer Vaccines , Modulators of TME and Inducers of T-cells for Adoptive T-cell Therapy
Jacobs Family Endowed Chair in Immunology, Roswell Park Comprehensive Cancer Center, Buffalo NY, USA
Immune Programs Associated to Tumoral Tertiary Lymphoid Structures at Different Maturation Stages in Early-stage Lung Adenocarcinoma
Director of the Immunohistochemistry and Digital Pathology Laboratory & Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA
Defining platinum-ineligibility: I know it when I see it?
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, USA
Translating C3 inhibition in periodontal inflammation
University of Pennsylvania, Penn Dental Medicine, Philadelphia, Pennsylvania, USA.
A practical approach to selection of first-line treatment for metastatic urothelial cancer
Dana Farber Cancer Institute, Harvard Medical School, Boston, USA
T cell immune signatures triggered by Mycobacteria
La Jolla Immunology Institute, San Diego, California USA
Immunobiology personalized approaches in oncology
Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy
Defining an ‘unfilt’ patient for Cisplatin-based chemo for the upfront treatment of metastatic urothelial carcinomas
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, USA
Multiomics approaches to define actionable targets in malignant pleural mesothelioma
UT MD Anderson Cancer Center, Houston, TX, US
Understanding the Genomic Landscape of Advaced Prostate Cancer
Medical Director, Ruttenberg Treatment Center, Tisch Cancer Institute, Mount Sinai Hospital, NY, USA.
Myeloid derived Suppressor cells: key players in shaping the delicate balance between inflammation and immune-suppression in COVID-19 patients
National Institute for Infectious Diseases-IRCCS L. Spallanzani, Rome, Italy
Improving outcomes for patients with non-castrate (castration-sensitive) prostate cancer
Medical Director, Genitourinary Oncology Research Program, Weill Cornell Medical College, New York, USA
Whole blood tests to measure T cell specific response in infectious diseases
National Institute for Infectious Diseases-IRCCS L. Spallanzani, Rome, Italy
Complement therapeutics in hematological disorders: lessons from PNH
AORN Moscati Avellino, Italy and Federico II University of Naples, Naples, Italy
Mycobacterial growth control in natural vs vaccine induced protection
Leiden University Medical Center, Leiden, The Netherlands
Development of targeted immunotherapy for HER2 tumors
Department of Pathology, Perelman School of Medicine, Philadelphia, USA.
Immune diagnostic tests for Echinococcosis
National Institute for Infectious Diseases-IRCCS L. Spallanzani, Rome, Italy
Network-Based Omics Approach Enables Precision Medicine Diagnostics and Drug Development
Scipher Medicine Corp, Waltham, MA
Treatment of Metastatic Castration Sensitive Prostate Cancer
Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, USA
Host directed therapies against mycobacterial infections
Università Cattolica del Sacro Cuore, Rome, Italy
Targeting complement: from benchside to bedside | Round Table Discussion
Democritus University of Thrace (DUTH), University Hospital of Alexandroupolis, Greece
Deep Spatial Profiling of the Tuberculosis Lung
Emory Vaccine Center Emory National Primate Center, Emory University, Atlanta, GA, USA
Complement Immunobiology
National Center for Scientific Research ‘Demokritos’, Athens, Greece
Coupling vitiligo development and therapeutic efficacy: a new challenge for immunotherapy in cutaneous melanoma
Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy
FOXP3 Instability and Treg cell-based therapy
Shanghai Institute of Immunology, SHSMU, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Engineering Bacterial Outer Membrane Vesicles for novel Immunotherapeutics
Department of Medicine, Surgery and Dentistry, Università degli Studi Salerno, Baronissi (SA), Italy
Severe Herpes Zoster Ophthalmicus: An Autobiographical Case Report
Hungarian Academy of Sciences & HepC Inc, Hungary
Future aspect of smart remote health monitoring in the midst of pandemic such as Covid
Kosin University College of Medicine, Pusan, South Korea
Expression of autoimmunity-related genes in melanoma
Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy
Arenavirus and odontogenic fibrous bone tumours: food-borne pathogens, eating habits and novel hypothesis
Saint Mary’s Hospital Lacor, Gulu, Uganda
Cysteamine: a new therapy for SARS-CoV-2?
National Institute for Infectious Diseases-IRCCS L. Spallanzani, Rome, Italy
Bispecific fusion proteins: targeting tumor cells or immune cells
Basic medical science, Tsinghua University, Beijing, China
Extracellular vesicle RNAs as diagnostics and future therapeutics in cancer
Department of Oncological Sciences, Icahn School of Medicine, New York, NY, USA